Adage Capital Partners GP L.L.C. Trims Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Adage Capital Partners GP L.L.C. reduced its position in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 20.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,500,000 shares of the company's stock after selling 900,000 shares during the period. Adage Capital Partners GP L.L.C. owned about 6.56% of TScan Therapeutics worth $10,640,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Prudential Financial Inc. purchased a new stake in shares of TScan Therapeutics in the fourth quarter valued at $32,000. China Universal Asset Management Co. Ltd. acquired a new stake in TScan Therapeutics in the 4th quarter worth about $32,000. Wells Fargo & Company MN grew its holdings in TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after buying an additional 5,694 shares during the period. Heck Capital Advisors LLC acquired a new position in shares of TScan Therapeutics during the 4th quarter valued at about $61,000. Finally, SG Americas Securities LLC lifted its holdings in shares of TScan Therapeutics by 31.2% during the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock worth $62,000 after acquiring an additional 4,852 shares during the period. 82.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on TCRX shares. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of TScan Therapeutics in a report on Thursday, March 6th. Barclays lowered their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and issued a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Wedbush restated an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday, March 5th. Finally, Morgan Stanley restated an "overweight" rating and issued a $10.00 price objective on shares of TScan Therapeutics in a report on Friday, March 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $9.33.

TScan Therapeutics Stock Down 7.0 %

Shares of NASDAQ TCRX opened at $1.60 on Monday. The stock has a fifty day moving average price of $1.61 and a 200 day moving average price of $2.96. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics, Inc. has a 12-month low of $1.02 and a 12-month high of $9.69. The company has a market cap of $90.55 million, a P/E ratio of -1.51 and a beta of 1.09.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $0.67 million during the quarter, compared to analysts' expectations of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

Want to see what other hedge funds are holding TCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.